Word

TIDES WUXI TIDES

Status

Pending

Status Code

688

Status Date

Tuesday, April 30, 2024

Serial Number

97909703

Mark Type

3

Filing Date

Thursday, April 27, 2023

Published for Opposition

Tuesday, March 5, 2024

Trademark Owner History

Shanghai SynTheAll Pharmaceutical Co., Ltd - Owner At Publication

Classifications

40 Metal treating; Material treatment information; Processing and handling of chemical reagents, namely, treatment of materials in the nature of chemicals; Cloth treating; Paper treating; Processing of oil; Stripping finishes, namely, treatment of wood for preservation purposes; Recycling of waste and trash; Air purification; Processing of medicinal materials being material treatment services in connection with recycling; Cryopreservation services; Providing information relating to material treatment; Custom assembling of materials for others being custom manufacture of pharmaceuticals, chemotherapy drugs, antibiotic medicines, and vaccines by pharmaceutical compounders; Processing of biomedical materials for others being biomanufacturing for others in the nature of manufacturing of pharmaceuticals and vaccines using biological organisms in the manufacturing process; Customized production service being custom manufacturing of pharmaceuticals; Custom manufacture of pharmaceuticals medical preparation

5 Prescription and non-prescription medicines, namely, pills, tablets, capsules, caplets, liquid drops, sachets and pharmaceutical preparations for the treatment of cancer, cardiovascular, hematologic, neurological, gastrointestinal and genetic diseases, inflammatory diseases, autoimmune diseases, infectious diseases, coagulation disorders, infectious and parasitic diseases, neoplasms, diseases of the blood and blood-forming organs, endocrine, nutritional and metabolic diseases, mental, behavioral and neurodevelopmental disorders, sleep-wake disorders, diseases of the nervous system, diseases of the respiratory system, diseases of the digestive system, diseases of the skin; Medicines for human purposes, namely, medicines for the treatment of cancer, cardiovascular, hematologic, neurological, gastrointestinal and genetic diseases, inflammatory diseases, autoimmune diseases, infectious diseases, coagulation disorders, infectious and parasitic diseases, neoplasms, diseases of the blood and blood-forming organs, endocrine, nutritional and metabolic diseases, mental, behavioral and neurodevelopmental disorders, sleep-wake disorders, diseases of the nervous system, diseases of the respiratory system, diseases of the digestive system, diseases of the skin; Drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; Raw material medicine, namely, medicines for the treatment of cancer, cardiovascular, hematologic, neurological, gastrointestinal and genetic diseases, inflammatory diseases, autoimmune diseases, infectious diseases, coagulation disorders, infectious and parasitic diseases, neoplasms, diseases of the blood and blood-forming organs, endocrine, nutritional and metabolic diseases, mental, behavioral and neurodevelopmental disorders, sleep-wake disorders, diseases of the nervous system, diseases of the respiratory system, diseases of the digestive system, diseases of the skin; Pharmaceutical preparations, for the treatment of cancer, cardiovascular, hematologic, neurological, gastrointestinal and genetic diseases, inflammatory diseases, autoimmune diseases, infectious diseases, coagulation disorders, infectious and parasitic diseases, neoplasms, diseases of the blood and blood-forming organs, endocrine, nutritional and metabolic diseases, mental, behavioral and neurodevelopmental disorders, sleep-wake disorders, diseases of the nervous system, diseases of the respiratory system, diseases of the digestive system, diseases of the skin; pharmaceutical preparations, namely, antivirals; Chemico-pharmaceutical preparations for the treatment of cancer, cardiovascular, hematologic, neurological, gastrointestinal and genetic diseases, inflammatory diseases, autoimmune diseases, infectious diseases, coagulation disorders, infectious and parasitic diseases; Biological preparations for medical purposes for the treatment of cancer, cardiovascular, hematologic, neurological, gastrointestinal and genetic diseases, inflammatory diseases, autoimmune diseases, infectious diseases, coagulation disorders, infectious and parasitic diseases; Chemical preparations for the diagnosis of pregnancy; Chemical preparations for pharmaceutical or medical purposes, for the treatment of cancer, cardiovascular, hematologic, neurological, gastrointestinal and genetic diseases, inflammatory diseases, autoimmune diseases, infectious diseases, coagulation disorders, infectious and parasitic diseases, neoplasms, diseases of the blood and blood-forming organs, endocrine, nutritional and metabolic diseases, mental, behavioral and neurodevelopmental disorders, sleep-wake disorders, diseases of the nervous system, diseases of the respiratory system, diseases of the digestive system, diseases of the skin; Chemical preparations for medical purposes, namely, chemical reagents for medical purposes; Chemical preparations for medical purposes; Diagnostic preparations for medical purposes; Nutritional supplements; Drugs for medical purposes; Reagent paper for medical purposes; Medical reagents; Disinfectants for hygiene purposes; Cultures of microorganisms for medical use; Biomedicine; Adjuvants for medical purposes; Vaccines; Veterinary preparations

42 Computer programming; Material testing; Technical research in the field of pharmaceutical studies; Research and development of new products for others; Technology consultancy in the field of cybersecurity; Chemical analysis; Chemistry services, namely, chemistry consultation; Chemical research; Biological research; conducting clinical trials for others, being for scientific and medical research; Quality checking and testing, namely, quality control for others; Scientific laboratory services; Genome structure and function analysis; Gene screening, namely, DNA screening for scientific research purpose; Biomedical research services; Stem cell research service; Drug research and development services, namely, pharmaceutical research; cell culture services for scientific research purposes, for others; Design and development of computer hardware and software; Development and creation of computer programs for data processing; Computer programming in the field of medical treatment; Product quality testing; assessment of quality of products; Scientific research; Surveying; Bacteriological research; The design, production in the nature of design, or maintenance of a computer program; Computer software design; Computer technology consultancy in the field of engineering; Information technology consulting relating to computer network design; Artificial intelligence technology consulting; Research on artificial intelligence technology; Research and development of new products; Pharmaceutical research services; Development of pharmaceutical preparations and medicines; Drug evaluation, namely, pharmaceutical product evaluation; Vaccine research and development services; Cancer medicine research; Biotechnology research; Drug testing being testing of pharmaceuticals; Pharmaceutical research; Cancer scientific research for medical purposes; Development and Testing of Chemical production methods; Implementation of early evaluation in the field of new drugs, namely, product quality testing; Biochemical research and analysis; Chemical analysis evaluation service; Chemical synthesis evaluation service; scientific research of the mode of action of chemical combinations on animals

Color is not claimed as a feature of the mark.
"WUXI"

Trademark Events

Oct 28, 2023

Assigned To Examiner

May 1, 2023

New Application Entered

May 25, 2023

New Application Office Supplied Data Entered

May 26, 2023

Notice Of Design Search Code E-Mailed

Nov 7, 2023

Non-Final Action Written

Nov 7, 2023

Non-Final Action E-Mailed

Nov 7, 2023

Notification Of Non-Final Action E-Mailed

Jan 5, 2024

Teas Change Of Owner Address Received

Jan 5, 2024

Applicant/Correspondence Changes (Non-Responsive) Entered

Jan 5, 2024

Teas Revoke/App/Change Addr Of Atty/Dom Rep Received

Jan 5, 2024

Attorney/Dom.Rep.Revoked And/Or Appointed

Jan 5, 2024

Teas Withdrawal As Domestic Representative Received

Jan 5, 2024

Teas Change Of Domestic Representatives Address

Jan 5, 2024

Teas Change Of Correspondence Received

Jan 8, 2024

Teas Response To Office Action Received

Jan 8, 2024

Correspondence Received In Law Office

Jan 9, 2024

Teas/Email Correspondence Entered

Jan 26, 2024

Approved For Pub - Principal Register

Feb 14, 2024

Official Gazette Publication Confirmation E-Mailed

Feb 14, 2024

Notification Of Notice Of Publication E-Mailed

Mar 5, 2024

Published For Opposition

Mar 5, 2024

Official Gazette Publication Confirmation E-Mailed

Apr 30, 2024

Noa E-Mailed - Sou Required From Applicant

Jul 4, 2024

Teas Statement Of Use Received